Hepatocellular carcinoma is a common disease
Cancer is the second most common cause of death worldwide and liver cancer is the second most common cause of cancer death. It accounted for 788,000 deaths in 2015 according to the World Health Organization: http://www.who.int/news-room/fact-sheets/detail/cancer. Hepatocellular carcinoma (HCC) is the most common type of liver cancer accounting for approximately 90% of all liver cancers, with average survival rates between 6 and 20 months.
Treatment with the TheraBionic P1
Until recently, only symptomatic treatment was advised for patients who have failed or are intolerant to first line and second line therapies for advanced hepatocellular carcinoma. As of 2018, a new treatment option is available for patients in the 28 countries of the European Economic Authority as well as in Iceland, Norway, Sweden and Switzerland.
The TheraBionic P1 device has received European regulatory approval as a breakthrough medical product for unmet medical needs for the treatment of patients with advanced hepatocellular carcinoma who have either failed or are intolerant to first line and second line therapies.
Comparison with the results from randomized studies conducted in patients with advanced hepatocellular carcinoma
This report describes a methodologically sound assessment of the therapeutic efficacy of the TheraBionic (TB) device by way of a statistical analysis of several studies. In this report the results of a single arm TheraBionic study are compared with control groups and treatment groups from two other studies. We examine three outcomes:
- Progression Free Survival
- Response Rate
- Overall Survival Among Patients who are not Child Pugh Class B